<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654066</url>
  </required_header>
  <id_info>
    <org_study_id>181420</org_study_id>
    <nct_id>NCT03654066</nct_id>
  </id_info>
  <brief_title>Botox or Botox With Esophageal Dilation in Patients With Achalasia</brief_title>
  <official_title>Prospective Single-Blinded Randomized Controlled Trial Comparing Botox or Botox With Esophageal Dilation in Patients With Achalasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Achalasia is a rare esophageal motility disorder. Treatment of achalasia is aimed toward
      palliation of symptoms. These include botox injections to the lower esophageal sphincter
      (LES), pneumatic dilation, surgical myotomy, and per-oral endoscopic myotomy (POEM). Botox
      injections are frequently used for patients that have significant comorbidities. The primary
      aim of this study is to assess symptomatic response of patient with achalasia to esophageal
      dilation and botox injection to the LES compared to standard therapy of only botox injection.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dysphagia score</measure>
    <time_frame>12 months</time_frame>
    <description>Dysphagia score as measured by patient reported outcomes will be used to compare the two groups. The scale runs from 0 (no symptoms) to 100 (severe symptoms).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Achalasia</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum toxin and dilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation. Subjects will also undergo distal esophageal dilation using a 20mm through the scope balloon positioned across the LES.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A</intervention_name>
    <description>Botox injection in the LES</description>
    <arm_group_label>Botulinum toxin</arm_group_label>
    <arm_group_label>Botulinum toxin and dilation</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endoscope balloon dilator</intervention_name>
    <description>Distal esophageal dilation</description>
    <arm_group_label>Botulinum toxin and dilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient reported outcomes</intervention_name>
    <description>Subjects will complete two patient reported outcome measures (Eckardt and MADS).</description>
    <arm_group_label>Botulinum toxin</arm_group_label>
    <arm_group_label>Botulinum toxin and dilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Barium esophagram</intervention_name>
    <description>Assess for radiologic severity of achalasia with barium column height measured 1 minute and 5 minutes after upright ingestion of barium</description>
    <arm_group_label>Botulinum toxin</arm_group_label>
    <arm_group_label>Botulinum toxin and dilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with known diagnosis of achalasia who are NOT candidates for definitive therapy
             with pneumatic dilation, surgical myotomy, or POEM

          -  Patient undergoing routine care upper endoscopy for achalasia

        Exclusion Criteria:

          -  Less than 18 years old

          -  Previous surgery for reflux or peptic ulcer disease

          -  Significant medical conditions possibly placing subjects at risk to undergo endoscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dhyanesh Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center Endoscopy Laboratory</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Dhyanesh Patel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Achalasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

